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A B S T R A C T
Polyomavirus virus associated nephropathy (PVAN) is an important cause of graft failure in the renal transplant pop-
ulation. The prevalence of PVAN has increased from 1% to 10% in the past decade, leading to loss of transplanted organ
in 30% to 80% of cases. In the absence of specific antiviral drugs, early detection of disease and modification/reduction of
immunosuppressive regimen is currently the cornerstone of therapy. In the setting of multiorgan transplantation, like si-
multaneous pancreas and kidney transplantation (SPKT), diagnosis and therapy of PVAN can be even more challenging
problem. We report a first described case of PVAN in patient after SPKT in Croatia. Patient is a 32 years old Caucasian
male with type 1 diabetes mellitus and end stage renal failure, diagnosed for PVAN 6 month after SPKT. Patient was
treated with reduced immunosuppressive regimen. At 32 month follow up, patient has preserved kidney and pancreas
function with estimated glomerular filtration (eGFR) rate of 91 mL/min and no signs of PVAN on his 2 year protocol kid-
ney biopsy.
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Introduction
Polyomavirus-associated nephropathy (PVAN) is cau-
sed by BK virus (BKV) and has emerged in the last de-
cade as one of major causes of allograft failure in renal
transplant recipients. Polyomavirus disease is defined as
histopathological or ultrastructural evidence of polyo-
mavirus induced cytopathic damage and organ involve-
ment1. The prevalence of PVAN has increased and now
ranges between 1% and 10%. This infection carries a
poor prognosis with reported renal allograft loss from
10% to >80%1,2. The majority of PVAN cases occur
within the first year posttransplantation, but approxi-
mately a quarter of cases are diagnosed later1.
Intense immunosuppression is perceived as a major
risk factor for PVAN. The majority of patients reported
to date received combinations containing tacrolimus and
mycophenolate mophetil (MMF)3. Brennan DC et al.
demonstrated, in prospective study, an increased risk of
tacrolimus-MMF-corticosteroid combination for BKV re-
plication and PVAN4.
In two major single center reports published on SPKT
patients, a relatively high incidence (6.2–7.5%) of PVAN
was noted. These reports have suggested that patients
with PVAN following SPKT may represent a difficult
subgroup of patients to manage compared with renal
transplant only recipients5.
Diagnosis of PVAN is based on the based on invasive
and non-invasive tests. Of nonivasive tests used are: 1)
cytology-detection of decoy cells in the urine which has a
high negative predictive value, but low positive predic-
tive value (PPV); 2) quantification of viral DNA by real
time polymerase chain reaction (PCR) in urine and plas-
ma. Plasma BK viral load of over 104 copies/mL is a sensi-
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tive and specific marker for PVAN with a positive predic-
tive value between 50–60%6,7,14. »Gold standard« in
diagnosing PVAN is renal biopsy together with immu-
nohistochemical analysis which utilizes monoclonal anti-
bodies toward viral proteins6. The mainstay of therapy is
prompt immunosuppressive dose reduction. It is not
clear weather the reduction or elimination of antimeta-
bolites is more effective than reduction of calcineurin in-
hibitor. No antiviral drug with proven efficacy against
the BKV has been licensed, but number of drugs have
been explored in small seris of cases like: cidofovir, lef-
lunomide and derivates, fluoroquinolones, intravenous
immunoglobulin7.
Case Report
We present a 32 year old Caucasian male with type 1
diabetes mellitus since he was eight years old, with
proliferative retinopathy and diabetic nephropathy
which progressed to renal failure four years prior to
transplantation. Since than patient was on intermittent
haemodialysis therapy. Patient undewent his first simul-
taneous kidney and pancreas transplantation (SPKT) in
November 2006. He received induction therapy with
daclizumab, tacrolimus, mycophenolat mofetil and ste-
roids and had immediate recovery of kidney and pan-
creas function.
His serum creatinine on discharge was 157 µmol/L
with estimated glomerular filtration rate (eGFR) of 63
mL/min. In the second month after SPKT his serum
creatinine was 104 µmol/L and eGFR was 101 mL/min.
Four month after SPKT he had an episode of sepsis
caused by Pseudomonas aeruginosa. At that point his
kidney function declined for about 30% which has after-
wards only partially recovered. Sixth. month after SPKT
his serum creatinine has increased to 137 µmol/L with
eGFR of 81 mL/min (Figure 1). Protocol urine cytology
screening at that point was positive for decoy cells. Kid-
ney allograft biopsy was performed at that time. Kidney
biopsy revealed dense tubulointerstital infiltrate with
mononuclear cells associated with edema and tubulitis
(Figure 3). BKV inclusions were proven by immuno-
histochemical analysis (Figure 4).
Therefore, we decided to minimize his immunosu-
pression therapy. We have reduced doses of both calcine-
urin inhibitor and mycophenolat mofetil (MMF) and ta-
pered steroids. Target levels of tacrolimus after PVAN
was diagnosed were 3–6 ng/mL, MMF dose was reduced
for 50% to a daily dose of 1000 mg/day and steroids were
tapered from 30 mg initially to 5 mg daily at 6 month af-
ter SPKT. During whole period of follow up patient re-
mained on minimized triple immunosupressive therapy
(Figure 2).
His kidney function was stabile with mean eGFR of
80 mL/min during follow up. At 1-year protocol kidney
biopsy, initial chronic changes were present with no signs
of rejection nor PVAN. Interstitial fibrosis and tubular
atrophy with dense mononuclear infiltrate was present
in about 15% of biopsy material of 15 glomeruli. Scor of
chronic changes was ci1, ct1, cg0, mm0, cv0, ah1 regard-
ing to Banff clasiffication8. Electron microscopy and
immunohistochemical analysis were negative for BKV.
S. Gracin et al.: Polyomavirus Nephropathy after Kidney and Pancreas Transplantation, Coll. Antropol. 34 (2010) 2: 623–626
624
eGFR (mL/min)
0
20
40
60
80
100
120
27.
11.
200
6
22.
12.
200
6
15.
1.2
007
29.
1.2
007
19.
3.2
007
16.
4.2
006
14.
5.2
007
11.
6.2
007
8.7
.20
07.
3.8
.20
07
3.1
0.2
007
5.1
2.2
008
7.2
.20
08
8.5
.20
08
9.7
.20
08
10.
11.
200
8
9.3
.20
09
1.6
.20
09
31.
8.2
009
eGFR (mL/min)
Fig. 1. Glomerular filtration rate (GFR) curve during 32 months
follow up. At 32 month follow up patient has GFR of 91.3 mL/min.
GFR was estimated by Cockroft Gault formula.
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Fig. 2. Serum concentrations of immunosuppressive drugs; ta-
crolimus (blue line) and mycophenolate mofetil (MMF) (red line)
during 32 month follow up. Since December 2007, serum concen-
trations of mycophenolate mofetil have been measured routinely
in our center.
Fig. 3. Hystology finding of PVAN in kidney allograftof by light
microscopy (hemalaun eosin staining). It shows diffuse mononu-
clear cell infiltration,heavy tubulitis (>10 lymphocytes on 10 tu-
bular epithelial cells). Many tubular epithelial cells express nu-
clear vacuolisation and viral inclusions.
His renal function declined for 10 mL/min 2.5 years after
SPKT (95.5 mL/min to 84 mL/min). Kidney biopsy was
done and revealed borderline acute cellular rejection and
mild to moderate chronic changes (Banff ’97). Scor of
acute changes was: i1, t2, g0, v0, ptc0, C4d0 and score of
chronic changes was: ci1, ct1,cg0, mm0, cv0, ah18. Im-
munohystochemical analysis was negative to BKV. Pa-
tient received a course of steroid antirejection therapy.
On his last visit, his creatinine level is 120 µmol/L and
eGFR is 91 mL/min. Endocrine and exocrine pancreas
function were normal. Negativization of decoy cells in
urin has never been achived. Quantification PCR test for
BKV in plasma was not available in Croatia until Sep-
tember 2009 so unfortunately we were not able to follow
up viraemia in this patient.
Discussion and Conclusion
Polyomavirus associated nephropathy has emerged as
an important cause of allograft loss and renal disfunction
in renal transplant recipients1,2. Use of tacrolimus com-
pared to cyclosporine, or MMF compared to azatioprine,
in maintainance immunosuppression has been impli-
cated as an important determinant of BK viruria, vire-
mia and nephrophaty4. Prevalence of PVAN in different
centers ranges from 1% to 10%1,2.
We have presented first case of PVAN after SPKT in
Croatia. Both allografts have been successfully preserved
during 32 month of follow up by minimization of mainte-
nance immunosuppressive therapy only. Goal levels of
tacrolimus during follow up were 3–6 ng/mL, MMF dose
was reduced by 50% (1000 mg daily) and steroid tapered
to 5 mg per day. Prevalence of PVAN in our center is 1.7%
or overall 3 patients. We have been able to successfully
preserve kidney allografts in 2 patients. One kidney
allograft has been lost due to multiple rejection episodes,
uncontrollable PVAN, one episode of humoral rejection
and surgical complications related to ureteral stenosis.
BK virus surveillance protocol in our center consists of:
cytology screening test for decoy cells in urine at 1, 3, 6,
12 months, protocol kidney biopsy at zero, 3 month, 6
month and 1 year time with immunohystochemical anal-
ysis for BKV when indicated. Since quantification PCR
test for BKV in plasma has become available in Croatia
at September 2009, it will be used monthly for the first 6
month after transplantation, every second month up to 1
year, than yearly.
Among 3 patients with PVAN in our center, this pa-
tient underwent treatment with minimization of immu-
nosuppression therapy, only. Because patient has had
stabile renal function during the follow up and no signs
of PVAN on 1 year protocol biopsy we have decided to
continue MMF without adding antiviral agent. Patient
had one biopsy proven acute cellular rejection episode 2.5
years after SPKT with no signs of PVAN. Looking back
on this case in 2006, we believe we should have per-
formed control renal biopsy earlier after PVAN was diag-
nosed rather than wait until one year protocol biopsy, es-
pecially in the setting of not being able to monitor BK
viraemia at that time.
There are different treatment approaches and one is
unlikely to be satisfactory until safe and effective antivi-
ral drugs are discovered. Different approaches to treat-
ment of BK nephropathy have been reported. Some cen-
ters use serial monitoring of viral load in urine and blood
and preemptively withdraw antimethabolites upon de-
tecting viraemia4, other use standard immunosuppres-
sion reduction9 or antiviral treatment13.Antiviral agents
used for treatment of BK nephropathy include cidofovir,
leflunomide, quinolone antibiotics and intravenous im-
munoglobulin1,11,13. Prospective randomized studies with
standardized treatment protocols are urgently required.
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Fig. 4. Positive immunohystochemisty staining for BKV
(brown coloured nuclei). BKV- BK virus.
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POLIOMAVIRUSOM UZROKOVANA NEFROPATIJA NAKON SIMULTANE TRANSPLANTACIJE
BUBREGA I GU[TERA^E – PRIKAZ SLU^AJA
S A @ E T A K
Poliomavirusom uzrokovana nefropatija (PVAN) va`an je uzrok disfunkcije i gubitka grafta bubrega nakon trans-
plantacije. Prevalencija PVAN-a se pove}ala od 1% do 10% u posljednjih 10 godina i uzrokom je gubitka grafta bubrega
u 30% do 80% slu~ajeva. Rana otkrivanje bolesti i modificiranje imunosupresivne terapije predstavljaju temelj lije~enja.
Specifi~na antiviralna terapija ne postoji. Dijagnostika i lije~enje PVAN u bolesnika nakon multiorganske transplan-
tacije, kao {to je simultana transplantacija bubrega i gu{tera~e (SPKT), predstavlja jo{ ve}i izazov. Ovdje predstavljamo
prvi opisani slu~aj PVAN-a u bolesnika nakon SPKT u Hrvatskoj. Bolesnik je bio bijelac u dobi od 32 godine, koji boluje
od tipa 1 {e}erne bolesti i terminalne kroni~ne bubre`ne insuficijencije i koji je lije~en simultanom transplantacijom
bubrega i gu{tera~e. PVAN je dijagnosticirana 6 mjeseci nakon SPKT. Lije~en je smanjenjem doze trojne imunosupre-
sivne terapijea (takrolimus, mikofenolat mofetil i steroidi). Bolesnik ima o~uvanu funkciju oba grafta nakon 32 mjeseca
pra}enja. Procijenjena glomerularna filtracija i znosi 91 mL/min bez znakova PVAN-a na protokol biopsiji bubrega
nakon 2 godine.
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